NCT03466502View on ClinicalTrials.gov

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

PHASE4CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 8, 2018

Primary Completion Date

February 17, 2022

Study Completion Date

February 17, 2022

Conditions
Clostridium Difficile Infection
Interventions
DRUG

Oral Vancomycin

Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence

Trial Locations (1)

89502

Renown Regional Medical Center, Reno

All Listed Sponsors
collaborator

Renown Regional Medical Center

OTHER

lead

University of Nevada, Reno

OTHER

NCT03466502 - Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics | Biotech Hunter | Biotech Hunter